CareerLocatorContactINVESTORS 
Skip to main content
SYNLAB

Patients & Individuals

Healthcare providers

Organisations
Newsroom Lab Locator Value of Diagnostics Partners of Expertise Quality Focus on patient health Career Investor Relations

   Medical Newsletter

Advances in Breast Cancer Care

 Back

Recent advancements in breast cancer research are enhancing both diagnosis and treatment, offering hope for more personalised and effective approaches. Key breakthroughs include the use of biomarkers such as BRCA and HER2 mutations, which provide critical insights into genetic predispositions and guide targeted therapies. Tumour-infiltrating lymphocytes (TILs) and genetic markers have emerged as important predictors of therapeutic response, side effects, and overall mortality. Metabolomics and epigenetic factors also play a role, revealing how the environment influences gene expression, impacting cancer progression and treatment outcomes.

The incorporation of next-generation sequencing (NGS) allows for more accurate diagnosis and recurrence risk assessments, enabling clinicians to tailor additional therapies. Pharmacogenetics is also improving, identifying genetic factors that predict toxicities associated with endocrine therapy. This ensures more personalised, effective treatments with fewer side effects. Additionally, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) are promising diagnostic markers, shedding light on cancer progression and offering new avenues for early detection.

Emerging technologies, such as ultrasound paired with clinicopathological data, enhance diagnosis accuracy, particularly in high-risk groups such as young women. The microbiome's role in cancer and the potential of exosomes as diagnostic tools are being actively explored, while tumour DNA in metastatic breast cancer offers a new frontier for monitoring disease progression and survival outcomes. As breast cancer research advances, gene therapy, immunotherapy strategies targeting regulatory T cells (Tregs), and novel treatments based on post-translational modifications of histological biomarkers are shaping the future of breast cancer care. With continued innovation, these breakthroughs hold promise for improving survival rates and quality of life for patients.

 

Recent key publications

 

Triple-Negative Breast Cancer EVs Modulate Growth and Migration of Normal Epithelial Lung Cells.
Int J Mol Sci 2024; 25. Leone I, Santoro J, Soricelli A et al.

 Link to full article:http://www.ncbi.nlm.nih.gov/pubmed/?term=38892050

Exosomes have emerged as promising biomarkers in cancer diagnosis and prognosis, given their role in cellular communication and their diverse molecular cargo, including nucleic acids, proteins, and lipids. These small extracellular vesicles provide valuable insights into tumour characteristics and progression. Despite their potential, challenges such as standardisation in isolation and clinical scalability remain. This article delves into the latest technological advancements and integrative approaches that enhance the diagnostic capabilities of exosomes, offering new perspectives on overcoming these obstacles and maximising their clinical utility.

LncRNAs involvement in pathogenesis of immune-related disease via regulation of T regulatory cells, an updated review.
Cytokine 2024; 179:156585. Khalilollah S, Kalantari Soltanieh S, Obaid Saleh R et al.

 Link to full article:http://www.ncbi.nlm.nih.gov/pubmed/?term=38579428

Long non-coding RNAs (lncRNAs) are seen as crucial regulators of immune cell differentiation and function, particularly in relation to regulatory T cells (Tregs) and their role in autoimmune diseases, cancer, and other immune-related conditions. These lncRNAs influence the balance between pro-inflammatory Th17 cells and immunosuppressive Tregs, which is critical for maintaining immune homeostasis. Understanding the molecular mechanisms of lncRNA-mediated Treg differentiation could provide insights into novel therapeutic strategies for a range of diseases where immune dysregulation is a central feature. This article offers an in-depth review of the current knowledge on lncRNAs, focusing on their impact on Treg differentiation and potential clinical applications.

Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer.
Cancer Biol Ther 2024; 25:2405060. Xu Y, Qi Y, Lu Z et al.

 Link to full article:http://www.ncbi.nlm.nih.gov/pubmed/?term=39304993

Advancements in precision medicine have significantly impacted the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer. This article explores the critical role of next-generation sequencing (NGS) in assessing recurrence risk, which enables the customisation of adjuvant therapy for patients. By integrating genomic data and clinical parameters, NGS-based tools such as Oncotype DX and MammaPrint help to refine treatment strategies, potentially minimising overtreatment and associated side effects. The comprehensive review of current genomic assays and their implications in clinical decision-making underscores the necessity of personalised treatment approaches to optimise patient outcomes.

Follow our newsletter and stay tuned for the upcoming, where we'll delve into the latest discoveries shaping the future of diagnostic and therapeutic approaches. Join us as we navigate the ever-evolving landscape of medical research, bringing you the most promising developments in the field.

 Follow on Linkedin

 Back  read more

Keywords: